May 9 Endo International Plc reported a higher-than-expected adjusted quarterly profit, driven by strong demand for its newly launched generics as well as its branded drugs.
However, the drugmaker's net loss attributable to shareholders widened to $173.8 million, or 78 cents per share, in the first quarter ended March 31 from $133.9 million, or 60 cents per share, a year earlier.
Excluding items such as an impairment charge of $204 million, Endo earned $1.23 per share, well above the average analysts' estimate of $1.10 per share, according to Thomson Reuters I/B/E/S.
Total revenue rose 7.7 percent to $1.04 billion, narrowly beating estimates of $1.02 billion.
The Dublin, Ireland-based drugmaker also reaffirmed its full-year adjusted profit forecast from continuing operations of $3.45 per share to $3.75 per share on revenue of $3.45 billion to $3.60 billion. (Reporting by Divya Grover in Bengaluru; Editing by Anil D'Silva)
UPDATE 7-Japanese air bag maker Takata files for bankruptcy, gets China backing
* Honda says no final agreement on recall liabilities (Adds details on restructuring, court hearing set for Tuesday, trims some material)
U.S., Colorado sue PDC Energy over alleged Clean Air Act violations
WASHINGTON, June 26 The Trump administration and the state of Colorado on Monday filed a civil complaint in federal court against PDC Energy Inc alleging violations of the Clean Air Act.